The Economic Tsunami of Liver Disease: Echosens Publishes New White Paper, Highlights Impact on U.S. Financial Solvency

Dr. Harrison says, “In this white paper, we explore the growing body of data that show how nonalcoholic fatty liver disease (NAFLD) is becoming recognized as a significant burden to patients, providers, and the overall healthcare system. One study concluded that the costs associated with the care for NAFLD were significantly higher than matched controls with similar metabolic profiles, even before the introduction of pharmacological treatments.”

He stresses that recent advances in diagnosis make it possible for PCPs to be more proactive and efficient in the screening of patients with T2DM and NAFLD. NAFLD, which affects roughly 100 million Americans, costs $32 billion annually to the U.S. healthcare system, almost as much as the $34 billion annual costs of strokes.

“In this white paper, we explore and establish the role of clinicians, including PCPs, to utilize cost effective risk stratification tools, such as FibroScan, a painless five-minute procedure as part of an overall workup to help diagnose NALFD early on,” explains Dr. Harrison. “As part of an overall patient assessment at the point of care, non-invasive FibroScan based assessments may reduce the significant specialist referral costs and with earlier identification of potentially advancing disease, support earlier interventions to improve outcomes.”

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. http://www2.echosens.com/AboutFibroScan https://www.echosens.us

View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005694/en/